Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy Sells 10,757 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.10, for a total value of $97,888.70. Following the sale, the chief financial officer now owns 226,097 shares of the company's stock, valued at approximately $2,057,482.70. This represents a 4.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Mineralys Therapeutics Price Performance

Shares of MLYS stock traded down $0.33 on Thursday, hitting $9.50. The company's stock had a trading volume of 251,290 shares, compared to its average volume of 288,644. The stock has a market capitalization of $472.82 million, a price-to-earnings ratio of -2.91 and a beta of 1.49. Mineralys Therapeutics, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $16.91. The firm's fifty day moving average price is $12.37 and its 200-day moving average price is $12.49.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its earnings results on Monday, November 11th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same quarter in the prior year, the company posted ($0.57) earnings per share. Analysts predict that Mineralys Therapeutics, Inc. will post -3.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Mineralys Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its position in Mineralys Therapeutics by 72.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 84,762 shares of the company's stock worth $992,000 after acquiring an additional 35,634 shares during the last quarter. Rhumbline Advisers boosted its stake in Mineralys Therapeutics by 82.1% during the 2nd quarter. Rhumbline Advisers now owns 41,079 shares of the company's stock valued at $481,000 after purchasing an additional 18,519 shares during the period. American Century Companies Inc. increased its position in Mineralys Therapeutics by 3.2% in the 2nd quarter. American Century Companies Inc. now owns 743,140 shares of the company's stock worth $8,695,000 after buying an additional 23,170 shares during the period. Federated Hermes Inc. lifted its holdings in shares of Mineralys Therapeutics by 100.0% during the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock worth $140,000 after buying an additional 6,000 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Mineralys Therapeutics by 95.0% in the second quarter. Renaissance Technologies LLC now owns 61,800 shares of the company's stock valued at $723,000 after acquiring an additional 30,100 shares during the period. Institutional investors own 84.46% of the company's stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a research note on Tuesday, November 12th.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.